Details for Patent: 10,294,474
✉ Email this page to a colleague
Which drugs does patent 10,294,474 protect, and when does it expire?
Patent 10,294,474 protects REDEMPLO and is included in one NDA.
This patent has one hundred and ninety-three patent family members in thirty-nine countries.
Summary for Patent: 10,294,474
| Title: | Targeting ligands |
| Abstract: | Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds that are useful in directing the compounds to the in vivo target. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to a therapeutic compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism. |
| Inventor(s): | Zhen Li, Tao Pei, Agnieszka Glebocka, Michael Lawler, Fred Fleitz, Erich Altenhofer, Pankaj Kumar |
| Assignee: | Arrowhead Pharmaceuticals Inc |
| Application Number: | US15/452,324 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,294,474
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arrowhead | REDEMPLO | plozasiran sodium | SOLUTION;SUBCUTANEOUS | 219947-001 | Nov 18, 2025 | RX | Yes | Yes | 10,294,474 | ⤷ Start Trial | Y | Y | USE TO REDUCE TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,294,474
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 104754 | ⤷ Start Trial | |||
| Argentina | 106227 | ⤷ Start Trial | |||
| Argentina | 108217 | ⤷ Start Trial | |||
| Argentina | 121850 | ⤷ Start Trial | |||
| Australia | 2016233364 | ⤷ Start Trial | |||
| Australia | 2016270593 | ⤷ Start Trial | |||
| Australia | 2016270597 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
